Matinas BioPharma Holdings Inc (NASDAQ:MTNB) will be releasing its earnings data on Monday, November 13th. Analysts expect Matinas BioPharma Holdings to post earnings of ($0.05) per share for the quarter.
Shares of Matinas BioPharma Holdings Inc (MTNB) opened at $1.12 on Friday. Matinas BioPharma Holdings Inc has a 12-month low of $1.01 and a 12-month high of $3.99.
Several equities research analysts recently weighed in on the company. Roth Capital set a $9.00 price objective on Matinas BioPharma Holdings and gave the stock a “buy” rating in a report on Thursday, August 10th. Maxim Group set a $6.00 price objective on Matinas BioPharma Holdings and gave the stock a “buy” rating in a report on Tuesday, August 8th.
In other news, Director Adam K. Stern acquired 100,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was bought at an average price of $1.38 per share, with a total value of $138,000.00. Following the acquisition, the director now owns 793,992 shares in the company, valued at approximately $1,095,708.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders purchased 110,000 shares of company stock valued at $151,250.
An institutional investor recently bought a new position in Matinas BioPharma Holdings stock. California State Teachers Retirement System bought a new position in Matinas BioPharma Holdings Inc (NASDAQ:MTNB) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 93,500 shares of the company’s stock, valued at approximately $158,000. California State Teachers Retirement System owned 0.10% of Matinas BioPharma Holdings as of its most recent SEC filing.
WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/11/12/matinas-biopharma-holdings-inc-mtnb-to-release-earnings-on-monday.html.
Matinas BioPharma Holdings Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.